ERBB2 and neoplasm: Additionally, we aimed to assess whether modern parameters such as established risk factors as MonarchE study inclusion criteria (four or more positive nodes, or one to three nodes and either tumour size ≥5 cm, histologic grade 3, or central Ki-67 ≥20%), HER2-low status, and samples from secondary primaries can predict the RS [14, 15].